当前位置： SCI文献检索 > BONE MARROW TRANSPLANTATION期刊下所有文献 > Incidence and severity of crucial late effects after allogeneic HSCT for malignancy under the age of 3 years: TBI is what really matters.

Incidence and severity of crucial late effects after allogeneic HSCT for malignancy under the age of 3 years: TBI is what really matters.

Abstract：

:Younger children are considered to be more vulnerable to late effects (LE), which prompted us to study LE in patients after haematopoietic stem cell transplantation (HSCT) for a haematological malignancy before the age of 3. In this multicentre EBMT study, cumulative incidence (CI) and severity of endocrine LE, central nervous system complications and secondary malignancies at 5, 10, 15 and 20 years of follow-up were assessed. Risk factors (RF) like gender, diagnosis, age at and year of HSCT, TBI- or chemo-conditioning and GVHD were analysed. CI of any LE was 0.30, 0.52, 0.66 and 0.72 at 5, 10, 15 and 20 years after HSCT, respectively. In 25% of the patients, LE were severe at a median follow-up of 10.4 years. In multivariate analysis, only TBI was a RF for having any LE and for thyroid dysfunction and growth disturbance. Female gender was a RF for delayed pubertal development. Some more insight could be gained by descriptive analysis regarding the role of TBI and GVHD on the severity of LE. Although only five selected LE have been studied and median follow-up is relatively short, the incidence and severity of these LE are considerable but not different from what has been found in older children and TBI is the main RF.

journal_name

Bone Marrow Transplant

journal_title

Bone marrow transplantation

authors

Bresters D,Lawitschka A,Cugno C,Pötschger U,Dalissier A,Michel G,Vettenranta K,Sundin M,Al-Seraihy A,Faraci M,Sedlacek P,Versluys AB,Jenkins A,Lutz P,Gibson B,Leiper A,Diaz MA,Shaw PJ,Skinner R,O'Brien TA,Salooja

doi

10.1038/bmt.2016.139

subject

Has Abstract

pub_date

2016-11-01 00:00:00

pages

1482-1489

issue

11

eissn

0268-3369

issn

1476-5365

pii

bmt2016139

journal_volume

51

pub_type

杂志文章,多中心研究

相关文献

BONE MARROW TRANSPLANTATION文献大全
  • Adult respiratory syndrome following autologous bone marrow transfusion.

    abstract：:Autologous bone marrow transplantation was performed in a 48-year-old man with relapsed high grade lymphoma. Two hours after the marrow infusion he developed pulmonary infiltrates and adult respiratory distress syndrome (ARDS). The aetiology of ARDS in this setting is uncertain but probably relates to pulmonary infect...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Roy V,Veys P,Jackson F,Ryan J,Lowdell M,Newland AC

    更新日期：1989-11-01 00:00:00

  • Late cytomegalovirus polyradiculopathy following haploidentical CD34+-selected hematopoietic stem cell transplantation.

    abstract：:A 55-year-old man with acute myeloid leukemia in second relapse presented 4 months after haploidentical CD34+-selected hematopoietic stem cell transplantation (HSCT) with symmetric, progressive neurological deficits of the lower extremities. Although there was no molecular evidence for drug resistance in the cerebral-...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1704311

    authors： Zeiser R,Grüllich C,Bertz H,Pantazis G,Hufert FT,Bley TA,Finke J

    更新日期：2004-01-01 00:00:00

  • Inhaled corticosteroids stabilize constrictive bronchiolitis after hematopoietic stem cell transplantation.

    abstract：:Post transplantation constrictive bronchiolitis (PTCB) is the most common pulmonary complication among long-term survivors of allogeneic hematopoietic stem cell transplantation (HSCT). It is a late manifestation of GVHD. Its treatment with high-dose systemic corticosteroids and other immunosuppressive regimens is asso...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1705877

    authors： Bashoura L,Gupta S,Jain A,Couriel DR,Komanduri KV,Eapen GA,Safdar A,Broglio KR,Adachi R,Dickey BF

    更新日期：2008-01-01 00:00:00

  • Early recovery of aggressive cytotoxic cells and improved immune resurgence with post-transplant immunotherapy for multiple myeloma.

    abstract：:A phase I/II trial evaluated early administration and dose escalation of interleukin (IL)-2 with granulocyte macrophage colony stimulating factor (GM-CSF) post-transplant. Following melphalan (200 mg/m(2)) and an autologous transplant, IL-2 was initiated (day 0) and continued for 4 weeks. GM-CSF (250 mcg/m(2)/day) beg...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1705665

    authors： Meehan KR,Wu J,Bengtson E,Hill J,Ely P,Szczepiorkowski Z,Kendall M,Ernstoff MS

    更新日期：2007-06-01 00:00:00

  • Disseminated fungal infection and early onset microangiopathy after allogeneic bone marrow transplantation.

    abstract：:We report a patient who developed early onset microangiopathic hemolytic anemia (MAHA) and thrombocytopenia after allogeneic bone marrow transplantation (BMT). The clinical features and laboratory findings were not consistent with cyclosporin toxicity, graft-versus-host disease or cytomegalovirus infection as causativ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Grigg A,Clouston D

    更新日期：1995-05-01 00:00:00

  • Natural killer cells as effector cells of graft-versus-leukemia activity in a murine transplantation model.

    abstract：:The transfer of cytotoxic effector cells reduces the risk of relapse after allogeneic BMT. Two murine leukemia cell lines, A20 (B lymphocytic) and WEHI-3 (myelomonocytic), were used to investigate antileukemic effector mechanisms operating independently from graft-versus-host disease (GVHD). Different results were obt...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Uharek L,Glass B,Gaska T,Zeiss M,Gassmann W,Löffler H,Müller-Ruchholtz W

    更新日期：1993-01-01 00:00:00

  • Utilization of stored autologous PBSCs to support second autologous transplantation in multiple myeloma patients in the era of novel agent therapy.

    abstract：:Outcomes in multiple myeloma (MM) have improved significantly with novel agent therapy and autologous stem cell transplantation (ASCT). ASCTs are typically planned as either tandem or a single transplant with additional stored PBSCs available for a second salvage transplant. To accommodate these strategies, many cente...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2015.13

    authors： Phipps C,Linenberger M,Holmberg LA,Green D,Becker P,Connelly-Smith L,Klippel Z,Burwick N,Gopal A,Bensinger WI,Libby E

    更新日期：2015-05-01 00:00:00

  • Red blood cell support and alloimmunization rate against erythrocyte antigens in patients undergoing hematopoietic stem cell transplantation.

    abstract：:We retrospectively analyzed red blood cell (RBC) support and alloimmunization rate in 218 consecutive patients - 128 from the Pediatric Department and 90 from the adult Hematology Department - undergoing hematopoietic stem cell transplantation (HSCT) between 1994 and 2000. In the pre-HSCT period, the pediatric patient...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1704114

    authors： Perseghin P,Balduzzi A,Galimberti S,Dassi M,Baldini V,Valsecchi MG,Pioltelli P,Bonanomi S,Faccini P,Rovelli A,Pogliani EM,Uderzo C

    更新日期：2003-07-01 00:00:00

  • Pulmonary hypertension is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation for myelofibrosis.

    abstract：:Allogeneic hematopoietic cell transplantation (alloHCT) is the only curative therapy for primary myelofibrosis (MF) as well as myelofibrosis secondary to other myeloproliferative neoplasms (MPN). Pulmonary hypertension (PH) is a known complication of MF and may occur in up to 50% of such patients. PH (defined as a mea...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/s41409-019-0741-8

    authors： Gupta R,Jamal F,Yang D,Chendri C,Aldoss I,Malki MA,Mei M,Salhotra A,Dobrin S,Tran M,Venkataraman K,Palmer J,Stein AS,Sandhu K,Khaled S,Aribi A,Marcucci G,Forman SJ,Snyder D,Nakamura R,Ali H,Pullarkat V

    更新日期：2020-05-01 00:00:00

  • Allogeneic transplantation after a conditioning regimen with ifosfamide, carboplatin and etoposide (ICE).

    abstract：:Successful allogeneic hematopoietic transplants require conditioning regimens with sufficient immunosuppression to allow acceptance of the allograft. Cyclophosphamide, in combination either with TBI or with chemotherapeutic drugs, is the keystone of commonly used regimens. The toxicities of TBI and tumor resistance to...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1700905

    authors： Oblon DJ,Paul S,Yankee R

    更新日期：1997-09-01 00:00:00

  • Allogeneic stem cell transplantation in second rather than first complete remission in selected patients with good-risk acute myeloid leukemia.

    abstract：:Through two consecutive trials, a policy that considered allogeneic stem cell transplantation (SCT) from a sibling donor in second rather than first complete remission (CR) in selected younger patients with acute myeloid leukemia (AML) with t(8;21)/inv(16) (core binding factor (CBF) group) or a normal karyotype (NN gr...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章

    doi：10.1038/sj.bmt.1704884

    authors： de Labarthe A,Pautas C,Thomas X,de Botton S,Bordessoule D,Tilly H,de Revel T,Bastard C,Preudhomme C,Michallet M,Fenaux P,Bastie JN,Socié G,Cordonnier C,Dombret H,Acute Leukemia French Association.

    更新日期：2005-04-01 00:00:00

  • CR represents an early index of potential long survival in multiple myeloma.

    abstract：:To assess the impact of CR on survival in multiple myeloma. Retrospective evaluation of response and survival among 758 consecutive patients with multiple myeloma treated at a single center, of whom 395 patients received intensive therapy supported by autologous stem cells within the first year. Survival times were ca...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2009.176

    authors： Wang M,Delasalle K,Feng L,Thomas S,Giralt S,Qazilbash M,Handy B,Lee JJ,Alexanian R

    更新日期：2010-03-01 00:00:00

  • Autologous BMT in high risk patients with CALLA-positive ALL: possible efficacy of ex vivo marrow leukemia cell purging with monoclonal antibodies and complement.

    abstract：:Autologous BMT (auto-BMT) has been conducted for 17 high-risk common ALL antigen (CALLA)-positive non-T cell type ALL patients. Ex vivo purging of leukemia cells from infused BM cells was performed using complement and three kinds of mouse monoclonal antibodies reactive to CALLA-positive leukemia cells: NL-1 (IgG2a), ...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章

    doi：

    authors： Morishima Y,Miyamura K,Kojima S,Ueda R,Morishita Y,Sao H,Tanimoto M,Ohno R,Sobue R,Hirano M

    更新日期：1993-04-01 00:00:00

  • Value of surveillance blood culture for early diagnosis of occult bacteremia in patients on corticosteroid therapy following allogeneic hematopoietic stem cell transplantation.

    abstract：:Bloodstream infection (BSI) is a significant complication following allogeneic hematopoietic stem cell transplantation (allo-SCT). Corticosteroids mask inflammatory responses, delaying the initiation of antibiotics. We reviewed medical records of 69 allo-SCT patients who had been on >0.5 mg/kg prednisolone to investig...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1704830

    authors： Chizuka A,Kami M,Kanda Y,Murashige N,Kishi Y,Hamaki T,Kim SW,Hori A,Kojima R,Mori SI,Tanosaki R,Gomi H,Takaue Y

    更新日期：2005-03-01 00:00:00

  • Donor lymphocyte infusions for refractory pure red cell aplasia relapsing after both autologous and nonmyeloablative allogeneic peripheral stem cell transplantation.

    abstract：:Pure red cell aplasia (PRCA) is characterized by a selective marrow aplasia of the erythroid compartment. Immunosuppressive therapy achieves good results in about 25% of cases, but relapses are frequent. Autologous or allogeneic haematopoietic stem cell transplantation (HSCT) may be valuable in selected patients. Here...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1704419

    authors： Musso M,Porretto F,Crescimanno A,Polizzi V,Scalone R

    更新日期：2004-04-01 00:00:00

  • Graft-versus-myeloma.

    abstract：:Whereas patients with multiple myeloma continue to relapse after autologous transplantation and are unlikely to be cured, the probability of progression is less after allogeneic transplantation and a proportion of patients may be cured. This is attributable to an immunologically mediated graft-versus-myeloma (GVM) eff...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,评审

    doi：10.1038/sj.bmt.1701459

    authors： Mehta J,Singhal S

    更新日期：1998-11-01 00:00:00

  • Busulfan-melphalan in high-risk neuroblastoma: the 30-year experience of a single institution.

    abstract：:High-dose chemotherapy (HDC) was investigated in high-risk neuroblastoma (HR-NBL) to reduce the risk of relapse. We report the results of the 30-year experience of a cohort of patients with HR-NBL treated with high-dose (HD) busulfan (Bu)-containing regimens. From 1980 to 2009, 215 patients aged >1 year with stage 4 N...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2016.75

    authors： Proust-Houdemont S,Pasqualini C,Blanchard P,Dufour C,Benhamou E,Goma G,Semeraro M,Raquin MA,Hartmann O,Valteau-Couanet D

    更新日期：2016-08-01 00:00:00

  • Practices for cytomegalovirus diagnosis, prophylaxis and treatment in allogeneic bone marrow transplant recipients: a report from the Working Party for Infectious Diseases of the EBMT.

    abstract：:During the past few years major progress has been made in the diagnosis and therapy of CMV infection after allogeneic BMT. The aim of this survey was to investigate the use of diagnostic techniques, use of prophylaxis and the therapeutic strategies among members of the EBMT. Seventy centers from 20 countries responded...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Ljungman P,De Bock R,Cordonnier C,Einsele H,Engelhard D,Grundy J,Locasciulli A,Reusser P,Ribaud P

    更新日期：1993-10-01 00:00:00

  • Acute autoimmune hemolytic anemia following unrelated cord blood transplantation as an early manifestation of chronic graft-versus-host disease.

    abstract：:A 16-month-old girl diagnosed with osteopetrosis underwent an unrelated, partially matched (with major mismatch at A locus) cord blood stem cell transplant. Twelve months later she developed severe acute autoimmune hemolytic anemia (AIHA). Immunophenotype analysis of lymphocyte subsets 8 months post transplant showed ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1703087

    authors： Sevilla J,González-Vicent M,Madero L,Díaz MA

    更新日期：2001-07-01 00:00:00

  • Feasibility of clofarabine cytoreduction before allogeneic transplant conditioning for refractory AML.

    abstract：:To control disease before allogeneic hematopoietic cell transplantation (HCT) for relapsed/refractory AML, we used clofarabine cytoreduction. Seventeen patients received clofarabine 30-40  mg/m(2) i.v. daily for 5 days with plans to initiate conditioning during the nadir, 14 days later. Bone marrow biopsy 12 days afte...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2010.32

    authors： Locke FL,Artz A,Rich E,Zhang Y,van Besien K,Stock W

    更新日期：2010-12-01 00:00:00

  • Adenovirus infection rates in pediatric recipients of alternate donor allogeneic bone marrow transplants receiving either antithymocyte globulin (ATG) or alemtuzumab (Campath).

    abstract：:Infectious complications due to adenovirus are of increasing concern after allogeneic stem cell transplantation. Over the past 4 years, we have modified our conditioning regimens to use alemtuzumab in preference to anti-thymocyte globulin (ATG) for pediatric patients receiving stem cell transplants from alternate dono...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1705164

    authors： Myers GD,Krance RA,Weiss H,Kuehnle I,Demmler G,Heslop HE,Bollard CM

    更新日期：2005-12-01 00:00:00

  • Influence of total nucleated cell dose from marrow harvests on outcome in patients with acute myelogenous leukemia undergoing autologous transplantation.

    abstract：:This retrospective study was conducted to determine whether the total number of nucleated cells (TNC)/kg collected at marrow harvest was associated with outcome in 151 patients with acute myelogenous leukemia (AML) who received an autologous purged (n = 67) or non-purged (n = 84) marrow transplant. At the time of tran...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Demirer T,Gooley T,Buckner CD,Petersen FB,Lilleby K,Rowley S,Sanders J,Storb R,Appelbaum FR,Bensinger WI

    更新日期：1995-06-01 00:00:00

  • Low bone mineral density is associated with insulin resistance in bone marrow transplant subjects.

    abstract：:Post-BMT subjects have an increased bone fracture risk. Additionally, several factors were associated with osteopenia and osteoporosis in these individuals. We aimed to identify other factors associated with osteopenia and osteoporosis in allogeneic post-BMT subjects. We conducted a cross-sectional study with 47 allog...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2009.70

    authors： Faulhaber GA,Premaor MO,Moser Filho HL,Silla LM,Furlanetto TW

    更新日期：2009-06-01 00:00:00

  • Hepatitis B virus (HBV) infection and liver disease after allogeneic bone marrow transplantation: a report of 30 cases.

    abstract：:Among 145 consecutive patients undergoing bone marrow transplantation (BMT) for leukemia or aplastic anemia. 30 (21%) were found positive for hepatitis B surface antigen (HBsAg) in serum either before or after BMT. Their serologic profile and clinical outcome are described. Nine out of 30 patients were HBsAg positive ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Locasciulli A,Bacigalupo A,Van Lint MT,Chemello L,Pontisso P,Occhini D,Uderzo C,Shulman HM,Portmann B,Marmont AM

    更新日期：1990-07-01 00:00:00

  • Sensitivity of secondary acute myeloid leukemia relapsing after allogeneic bone marrow transplantation to immunotherapy with interferon-alpha 2b.

    abstract：:A patient with acute myeloid leukemia secondary to therapy of choriocarcinoma underwent T cell non-depleted allogeneic bone marrow transplantation from an unrelated donor in first untreated relapse. Persistent/relapsed leukemia 4 months after transplantation did not respond to cessation of cyclosporine. Due to logisti...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1700793

    authors： Singhal S,Powles R,Treleaven J,Mehta J

    更新日期：1997-06-01 00:00:00

  • Predicting non-relapse mortality following allogeneic hematopoietic cell transplantation during first remission of acute myeloid leukemia.

    abstract：:The aim of this study was to develop a comprehensive system for predicting non-relapse mortality after allogeneic hematopoietic cell transplantation (HCT) during first complete remission (CR) of acute myeloid leukemia (AML). After dividing 2344 eligible patients randomly into a training set and a validation set, we fi...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/s41409-020-01032-9

    authors： Yanada M,Konuma T,Mizuno S,Saburi M,Shinohara A,Tanaka M,Marumo A,Sawa M,Uchida N,Ozawa Y,Onizuka M,Yoshioka S,Nakamae H,Kondo T,Kimura T,Kanda J,Fukuda T,Atsuta Y,Nakasone H,Yano S

    更新日期：2020-08-14 00:00:00

  • CD3(+) and/or CD14(+) depletion from cord blood mononuclear cells before ex vivo expansion culture improves total nucleated cell and CD34(+) cell yields.

    abstract：:Cord blood (CB) is used increasingly in transplant patients lacking sibling or unrelated donors. A major hurdle in the use of CB is its low cell dose, which is largely responsible for an elevated risk of graft failure and a significantly delayed neutrophil and platelet engraftment. As a positive correlation has been s...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2009.289

    authors： Yang H,Robinson SN,Lu J,Decker WK,Xing D,Steiner D,Parmar S,Shah N,Champlin RE,Munsell M,Leen A,Bollard C,Simmons PJ,Shpall EJ

    更新日期：2010-06-01 00:00:00

  • G-CSF serum pharmacokinetics during peripheral blood progenitor cell mobilization: neutrophil count-adjusted dosage might potentially improve mobilization and be more cost-effective.

    abstract：:The optimal dosing schedule of G-CSF for peripheral blood progenitor cell (PBPC) mobilization is still under investigation although many centers use 10 microg/kg/day in a single subcutaneous dose. However, G-CSF clearance increases with increasing absolute neutrophil count (ANC). Hence a G-CSF dosage adjusted to ANC m...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1701241

    authors： Faulkner LB,Tucci F,Tamburini A,Tintori V,Lippi AA,Bambi F,Malentacca F,Azzari C,Gelli AM,Genovese F,Bernini G

    更新日期：1998-06-01 00:00:00

  • Evaluation of optimal survival of primitive progenitor cells (LTC-IC) from PBPC apheresis products after overnight storage.

    abstract：:Optimal overnight (ON) storage of PBPC aphereses is becoming an increasingly important issue and different options for storing PBPC products exist. The survival of primitive progenitor cells is of major interest, as recent data suggest that these progenitors are not only important for long-term engraftment but also co...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1702104

    authors： Petzer AL,Gunsilius E,Zech N,Clausen J,Hoflehner E,Nussbaumer W,Gastl G

    更新日期：2000-01-01 00:00:00

  • Early measles vaccination in bone marrow transplant recipients.

    abstract：:Measles vaccination has been recommended after the second year following bone marrow transplant (BMT) in patients not receiving immunosuppressive drugs. During a measles outbreak, we vaccinated all patients after the first year of transplant, and conducted a prospective trial to evaluate safety, effectiveness and sust...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章

    doi：10.1038/sj.bmt.1704878

    authors： Machado CM,de Souza VA,Sumita LM,da Rocha IF,Dulley FL,Pannuti CS

    更新日期：2005-04-01 00:00:00